Latest Bone marrow Stories
The first ever fully synthetic organ transplant has been performed by surgeons at the Karolinska University Hospital in Stockholm, Sweden.
A stem cell that can morph into a number of different tissues is proving a natural protector, healer and antibiotic maker, researchers at Case Western Reserve University and their peers have found.
Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.
MELBOURNE, Australia, July 7, 2011 /PRNewswire/ -- Key points: Mesoblast's first Phase 3 trial submission cleared by United States Food and Drug Administration (FDA)Rapid clearance (within 30 days) further validation of Mesoblast's clinical, regulatory, and manufacturing capabilitiesMesoblast's proprietary adult stem cells expand hematopoietic precursor cells in umbilical cord blood 40-fold, enabling rapid bone marrow reconstitution with lowered risk of life-threatening Graft Versus Host...
'Novel' Reality Program Aims to Boost Breast Cancer, Leukemia Awareness...and Recruit New Bone Marrow Donors NEW YORK, June 13, 2011 /PRNewswire-USNewswire/ -- A legal thriller which tells the true story of a woman who battled breast cancer, then leukemia, and finally got a successful bone marrow transplant is being used to educate the public about the constant need for bone marrow donors.
The organization takes on Alice's wish in the U.S.
CLEVELAND, June 7, 2011 /PRNewswire-USNewswire/ -- Arteriocyte(TM), a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies, announced today that they have entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR) at Fort Sam Houston, Texas.
RANCHO CORDOVA, Calif., June 2, 2011 /PRNewswire/ -- ThermoGenesis Corp.
New-fangled research examines the therapeutic use of human stem cells from bone marrow against acute lung injury and identifies TNF-a-induced protein 6 as a foremost molecular component of stem cell action.
New research, published in BioMed Central's open access journal Stem Cell Research & Therapy, investigates the therapeutic use of human stem cells from bone marrow against acute lung injury and identifies TNF-Î±-induced protein 6 as a major molecular component of stem cell action.
Bone Marrow Transplantation is a peer-reviewed medical journal published monthly by Nature Publishing Group. As of May 2012, the editor-in-chief is J.M. Goldman (UK). The journal publishes high quality, original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation in humans. The broad scope of the journal thus encompasses topics such as stem cell biology, kinetics and cytokine control, transplantation immunology, HLA and matching...
- a slit in a tire to drain away surface water and improve traction.